AOD-9604 peptide claims on TikTok: what the science says

What did @bodycodeboss actually say?

The creator describes AOD-9604 as "a fragment of growth hormone" designed to help with "fat metabolism without any IGF-1 risks." They list three selling points: fat breakdown support, minimal blood sugar impact, and "mild joint support." They recommend injectable doses of 250 to 500 micrograms daily for 4 to 12 weeks, price it at $120 to $200 per month, and close with a disclaimer to consult a provider. The framing is cautious overall, with the creator calling it "not a miracle fat burner" and noting it works best alongside exercise. That measured tone deserves credit. But several of the underlying scientific claims need a harder look.

Does the science back this up?

Partially, and the word "partially" is doing a lot of work here. AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone (hGH176-191). Early animal studies were promising. Ng et al. (2000, Molecular and Cellular Endocrinology) showed the peptide stimulated lipolysis and inhibited lipogenesis in obese rodents without raising IGF-1 or affecting glucose tolerance. That is where the "no IGF-1 risk" and "little to no impact on blood sugar" claims originate, and they are reasonably grounded in preclinical data.

The human data is far thinner. Metabolic Pharmaceuticals ran Phase II and Phase III trials for oral AOD-9604 as an obesity drug in the early 2000s. Those trials failed. The compound did not produce statistically significant weight loss over placebo in humans (Heffernan et al., 2001, Journal of Clinical Endocrinology and Metabolism). The injectable form used today in wellness settings has not completed equivalent human trials. The joint support claim rests almost entirely on in vitro and animal osteoarthritis work, not human RCTs.

What did they get wrong (or right)?

They got the basic mechanism right. AOD-9604 does appear to act on beta-3 adrenergic receptors to stimulate fat breakdown, and it does this without the IGF-1 stimulation associated with full-length growth hormone. That distinction is real and worth making.

What they glossed over is significant. Calling the joint support benefit a feature of AOD-9604 without flagging that this evidence is almost entirely preclinical is misleading by omission. A 2014 study by Ryan et al. (Cartilage) showed chondroprotective effects in animal models, but no peer-reviewed human trial has confirmed clinical joint benefit from injectable AOD-9604. The creator also presents the 250-500 mcg dosing range as settled fact. It is not. That range is derived from compounding pharmacy protocols, not published dose-ranging studies in humans. Stating it without that caveat gives false confidence.

On the positive side, "it's not a miracle fat burner" is exactly the right message. The creator also correctly notes it works best alongside movement, which aligns with the mechanistic reality that lipolysis requires an energy deficit to produce net fat loss.

What should you actually know?

AOD-9604 is not FDA-approved for any indication. In 2015, the FDA removed it from the list of bulk drug substances that compounding pharmacies could use without a prescription drug application. It currently exists in a regulatory gray zone that varies by jurisdiction. Some compounding pharmacies still dispense it under practitioner supervision; others cannot legally do so depending on state law.

The safety profile in humans is not well characterized beyond short-term trial data. The peptide is generally described as well-tolerated in the trial literature, with injection site reactions being the most commonly reported adverse effect. Long-term safety data in humans essentially does not exist. Anyone considering this compound should understand they are working with incomplete evidence, not a validated clinical therapy. The creator's disclaimer to check with a provider is appropriate, but it should come with a stronger acknowledgment that this compound lacks robust human efficacy data, not just a vague nod to safety.